Publications by authors named "Rino Fukui"
Article Synopsis
- A study investigated the link between prior bevacizumab (BEV) therapy and the development of proteinuria in patients with metastatic colorectal cancer (mCRC) receiving ramucirumab (RAM) treatment.
- Results showed that patients with prior BEV treatment had a significantly higher risk of developing grade 2-3 proteinuria and a greater rate of RAM discontinuation due to related toxicities compared to those without prior BEV.
- The findings suggest that using FOLFIRI plus RAM soon after BEV treatment may worsen proteinuria and negatively affect overall survival, particularly if initiated within 55 days after BEV therapy.
Background: The concentration of trifluridine in tumor DNA was strongly correlated with that of white blood cells in tumor-bearing nude mice administered trifluridine-tipiracil (TAS-102). Further, a phase I study of TAS-102 in patients with advanced solid tumors showed a significant correlation between decreased neutrophil count and the area under the concentration-time curve of trifluridine. Herein, we aimed to evaluate the association of decreased neutrophil count with the efficacy of TAS-102.
View Article and Find Full Text PDFArticle Synopsis
- RAGE (receptor for advanced glycation endoproducts) inhibits chondrocyte differentiation and cartilage matrix production, with its expression found in prehypertrophic to hypertrophic regions of cartilage.
- Overexpression of RAGE negatively affects the production of important chondrocyte markers, while downregulation of certain genes (Cdxs) is key to its inhibitory effects.
- The study suggests that RAGE operates through NF-κB-independent and Rho family GTPases-dependent pathways to regulate chondrocyte differentiation during early stages of cartilage development.